FindTrial
Sign In

High-Dose Betahistine and Its Impact on Cognition and Metabolism in Schizophrenia patients

High Dose Betahistine In Schizophrenia Metabolic Effects And Cognitive Function - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/095310
Enrollment
40
Registered
2025-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20- Schizophrenia

Interventions

Intervention1: Betahistine drug: Group 1 will consist of 20 patients who will receive high-dose Betahistine at a total daily dose of 72 mg, divided into three doses for 8 weeks, in combination with th

Sponsors

Central Institute Of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Inpatients satisfying the ICD 10 DCR (1993) criteria for Schizophrenia 2 First episode schizophrenia (Duration less than or equal to 2 Years) 3 Age 18 to 50 years of either gender 4 Patients with Healthy BMI (18.5 to 24.9) and not fulfilling the criteria for Metabolic Syndrome 5 Patient currently on Tab. Olanzapine as Second Generation Antipsychotics 6 Score on MoCA less than 26 7 Moderately severe or less ( Less than or equal to 5) severity rating on PANSS items 8 Patients who give written informed consent for participating in the study.

Exclusion criteria

Exclusion criteria: 1 Any other major comorbid psychiatric diagnosis or significant concurrent medical illnesses 2 Pregnant or lactating female patients 3 Patients with organic brain disorder and or mental retardation 4 Patients on treatment with medications that can influence cognitive functioning like Anticholinergics (except trihexyphenidyl) 1st generation antipsychotics 5 Patients on treatment with medications that can influence metabolic profile 6 Patients on treatment with SSRI SNRI TCA or MAOI 7 Patients who have received ECT in the past 6 months

Design outcomes

Primary

MeasureTime frame
Tab. Betahistine (72mg per day in 3 divided doses) will help in improving the metabolic and cognitive effects in the patient of schizophrenia with OlanzapineTimepoint: Tab. Betahistine (72mg per day in 3 divided doses) will help in improving the metabolic and cognitive effects in the patient of schizophrenia with Olanzapine—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Surendra Paliwal

Central Institute Of Psychiatry

itsme.paliwal@gmail.com8005940887

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026